CD274 and non-small cell lung carcinoma: Other trials are currently investigating the immune-modulatory effects of different fractionation regimens of radiotherapy to enhance the effects of neoadjuvant PD-L1 blockade after neoadjuvant chemotherapy in patients with resectable stage III (N2) NSCLC.